SEARCH

SEARCH BY CITATION

References

  • 1
    Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 10048.
  • 2
    Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 51722.DOI: 10.1056/NEJM199402243300801
  • 3
    Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396400.
  • 4
    Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 31205.
  • 5
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van Der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 647.
  • 6
    Voorberg J, Roelse J, Koopman R, Büller H, Berends F, Ten Cate JW, Mertens R, Van Mourik JA. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 15356.DOI: 10.1016/S0140-6736(94)92939-4
  • 7
    Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 13612.DOI: 10.1016/S0140-6736(94)92497-X
  • 8
    Zöller B, Svensson PJ. He X. Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94(6): 25214.
  • 9
    Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 191420.
  • 10
    Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in FV R506Q. J Biol Chem 1995; 270: 40537.
  • 11
    Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995; 270: 20794800.DOI: 10.1074/jbc.270.35.20794
  • 12
    Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521.
  • 13
    Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130(8): 64350.
  • 14
    Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 91217.DOI: 10.1056/NEJM199504063321403
  • 15
    Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet 1993; 342: 15036.
  • 16
    Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai A, Yanez ND, Rosamond WD. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002; 99: 27205.
  • 17
    Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ III Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 12458.DOI: 10.1001/archinte.162.11.1245
  • 18
    Middeldorp S, Henkens CMA, Koopman MMW, Van Pampus ECM, Hamulyàk K, Van Der Meer J, Prins MH, Büller HR. The incidence of venous thromboembolism in family members of patients with Factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 1520.
  • 19
    Simioni P, Prandoni P, Girolami A. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation. Ann Intern Med 1999; 130(6): 538.
  • 20
    Simioni P, Sanson B-J, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Büller HR, Ten Cate JW, Girolami A, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198202.
  • 21
    Middeldorp S, Meinardi JR, Koopman MMW, Van Pampus ECM, Hamulyàk K, Van Der Meer J, Prins MH, Büller HR. A prospective study of asymptomatic carriers of the Factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135: 3227.
  • 22
    Simioni P, Tormene D, Prandoni P, Zerbinati P, Bavasso S, Cefalo P, Girolami A. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective study. Blood 2002; 99: 193842.
  • 23
    Lensen RPM, Bertina RM, De Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 81721.
  • 24
    Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 37480.DOI: 10.1056/NEJM200002103420602
  • 25
    Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 8003.
  • 26
    Gustafson S, Proper JA, Bowie EJW, Sommer SS. Parameters affecting the yield of DNA from human blood. Anal Biochem 1987; 165: 2949.DOI: 10.1016/0003-2697(87)90272-7
  • 27
    Okayama H, Curiel DT, Brantly ML, Holmes MD, Crystal RG. Rapid nonradioactive detection of mutations in the human genome by allele-specific amplification. J Lab Clin Med 1989; 114: 10513.
  • 28
    Sarkar GS, Cassidy J, Bottema CDK, Sommer SS. Characterization of polymerase chain reaction amplification of specific alleles. Anal Biochem 1990; 186: 648.DOI: 10.1016/0003-2697(90)90573-R
  • 29
    Kurland LT, Molgaard CA. The patient record in epidemiology. Scientific Am 1981; 245: 5463.
  • 30
    Melton LJ III History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 26674.
  • 31
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med 2000; 160: 80915.DOI: 10.1001/archinte.160.6.809
  • 32
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, cohort study. Arch Intern Med 1998; 158(6): 58593.DOI: 10.1001/archinte.158.6.585
  • 33
    Herrmann FH, Koesling M, Schröder W, Altman R, Jiménez Bonilla R, Lopaciuk S, Perez-Requejo JL, Singh JR. Prevalence of factor V Leiden in various populations. Genet Epidem 1997; 14: 40311.DOI: 10.1002/(SICI)1098-2272(1997)14:4<403::AID-GEPI5>3.0.CO;2-3
  • 34
    Juul K, Tybjærg-Hansen A, Schnohr P, Nordestagaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140: 3307.
  • 35
    Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277: 13057.DOI: 10.1001/jama.277.16.1305
  • 36
    Lee DH, Henderson PA, Blajchman MA. Prevalence of Factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996; 155: 2859.
  • 37
    Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 1996; 347: 1044.DOI: 10.1016/S0140-6736(96)90181-6
  • 38
    Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated Protein C). Blood 1997; 89: 19637.
  • 39
    Hasstedt SJ, Bovill EG, Callas PW, Long GL. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum General 1998; 63(2): 56976.DOI: 10.1086/301947
  • 40
    Scott BT, Bovill EG, Callas PW, Hasstedt SJ, Leppert MF, Valliere JE, Varvil TS, Long GL. Genetic screening of candidate genes for a prothrombotic interaction with type I protein C deficiency in a large kindred. Thromb Haemost 2001; 1002(85): 827.
  • 41
    Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 52831.
  • 42
    Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 10003.
  • 43
    Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 913.DOI: 10.1056/NEJM199901073400102
  • 44
    Rosendaal FR, Vessey MP, Rumley A , Daly E, Woodward M, Helmerhort FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 8514.DOI: 10.1046/j.0007-1048.2002.03356.x
  • 45
    Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983; 62: 23943.
  • 46
    Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Parwardhan NA, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 9338.DOI: 10.1001/archinte.151.5.933